Document is current
Any future updates will be listed below
-
Authors
Gerdes, Rieke https://orcid.org/0009-0000-9128-6670
Schittenhelm, Jens
Singer, Stephan
Reischl, Gerald
Becker, Hannes https://orcid.org/0000-0003-0306-1143
Tatagiba, Marcos
Castaneda-Vega, Salvador G.
la Fougère, Christian https://orcid.org/0000-0001-7519-0417
Bender, Benjamin
Trautwein, Nils F. https://orcid.org/0000-0003-3397-6299
-
Funding
Funding for this research was provided by:
Universitätsklinikum Tübingen
- License Information
-
More Information
Article History
Received: 17 February 2026
Accepted: 12 August 2026
First Online: 4 September 2026
Declarations
Ethics approval and consent to participate: The study was performed in accordance with the principles of the Declaration of Helsinki. This retrospective study was approved by the Institutional Review Board of the University Hospital of Tuebingen (089/2024BO2). Written informed consent was obtained from all patients in accordance with the provisions of the German Pharmaceuticals Act §13.2b. Each individual gave written informed consent to participate prior to imaging.
Consent for publication: Written informed consent was obtained from the participants for publication of this study and accompanying images.
Competing interests: N.T. received personal fees from Novartis outside the submitted work and was supported by the Clinician Scientist Program Tuebingen (525-0-0). An ongoing research collaboration exists between N.T. and C.l.F. with ABX. C.l.F. discloses research grant from Siemens Healthineers, Telix, and reports consulting fees from Siemens Healthineers, Novartis, Telix, Astra Zeneca and Bayer.
